Ehsan Gharib1, Shideh Montasser Kouhsari2, Maryam Izad3. 1. Department of Cellular and Molecular Biology, School of Biology, University College of Science, University of Tehran, Tehran, Iran. 2. Department of Cellular and Molecular Biology, School of Biology, University College of Science, University of Tehran, Tehran, Iran. Electronic address: montasser20sh@khayam.ut.ac.ir. 3. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
MicroRNAs (miRNAs) are small, non-coding RNA
molecules that play a central role in the regulatory network
of metabolic pathways (1). miR-145 is a member of the
miR-143-145 cluster and acts as a negative regulator
of insulin receptor substrate 1 (IRS-1) level by pairing
with the 3’-UTR region of irs-1 mRNA (2). Researchers
report upregulation of miR-145 in obesity and increased
lipolysis in adipocytes (3). As a result, miR-145 stimulates
hyperglycemia and hyperlipidemia due to insulin signaling
pathway disruption (4). Also, a recent study has reported
miR-145 upregulation in type 1 diabetes mellitus (T1DM)
patients and an animal model (5).The miR-145 expression level is associated with reactive
oxygen species (ROS) accumulation. Destruction of insulinsecreting
pancreatic β-cells in T1DM results in massive ROS
generation in response to mitochondrial defection (6). An
enhanced level of ROS content upregulates the p53 and p65
subunit of the transcription factor nuclear factor-κB (NF-κB)
complex expressions and transcriptional activities (7, 8),
which have a positive impact on miR-145 overexpression (8,
9). ROS is identified as a positive regulator of inflammatory
cytokines such as tumor necrosis factor-alpha (TNF-α);
therefore, it stimulates p65 induction of miR-145 expression
in an alternative way (9, 10).Punica granatum L. (pomegranate) is a widely used
plant and appears to be native in some parts of Asia,
particularly Iran. Extract of the pomegranate fruit has
a high polyphenolic content that includes punicalagin,
anthocyanins, ellagic acid, gallic acid, caffeic acid,
catechins, quercetin, and rutin (11). The pomegranate is
known as an antioxidant-rich fruit because of its positive
effects in limiting oxidative stress in humans (12) and
rats (13). Based on the main contribution of the liver
and skeletal muscle tissues in blood glucose homeostasis
(14), downregulation of miR-145 could be considered
a therapeutic method in obesity, metabolic syndrome,
and T1DM subjects. Due to the negative effects of the
pomegranate on ROS production, inflammation, p53
and p65 levels (15-17), we hypothesized that treatment
with the pomegranate fruit aqueous extract (PGE) could
ameliorate miR-145 levels in alloxan-induced diabeticrats (as an animal model for T1DM) via downregulation
of p53/p65 expressions. Therefore, we analyzed the expression levels of p53, p65, and miR-145, along with the
mRNA content of irs-1 in diabeticrats treated with different
doses of PGE compared to diabetic and healthy controls
Materials and Methods
In this experimental study, chemicals and reagents were
obtained from the following sources: Alloxan monohydrate
(Sigma, St. Louis, MO, USA), RNA Extraction kit
(SinaClon Co., Iran), PrimeScript RT Reagent kit
(TaKaRa Biotechnology, Japan), miRNA isolation kit and
Super SYBR Green qPCR Master Mix 2x (Yekta Tajhiz
Co., Iran), Universal cDNA synthesis kit II and ExiLENT
SYBR® Green PCR Master Mix (Exiqon, USA), RatReactive Oxygen Species ELISA kit (MyBioSource, San
Diego, CA, USA), Triglyceride Quantification Assay kit
(Abcam, USA), and commercial Free Fatty Acid Assay
kit (Enzychrom Bio-Assays Systems, USA). All other
chemicals and solvents were of the highest commercial
grade and purchased from either Merck (KGaA,
Germany) or Sigma (St. Louis, MO, USA). We purchased
male Wistar rats (Rattus norvegicus) that weighed 180-
220 g from the School of Pharmacy, Tehran University
of Medical Sciences (Iran). Animals were housed 4 per
standard rat cage in a room with a 12:12 hour light/dark
cycle and controlled temperature (24 ± 1˚C). The animals
were allowed to adapt to their new location for one week.
Animals received water and a standard diet (27% protein,
32% fat, and 41% carbohydrate) ad libitum.
Ethical consideration
All procedures that involved animals and their care that
included feeding, extract administration, blood sampling,
gastric intubation, anesthesia, and euthanasia were
under the close supervision of qualified and experienced
personnel, and approved by the Institutional Animal Care
and Use Committee of University of Tehran.
Preparation of the pomegranate fruit aqueous extract
Pomegranate fruits were washed and manually peeled
without separating the seeds. The extract was obtained
using a blender, filtered through Whatman No. 1 filter
paper to remove any water insoluble materials, and
then steamed (5 minutes) for enzyme inactivation.
In the next step, the extract was stored at -18˚C. The
extract subsequently underwent a drying process in a
cabinet dryer at 37˚C for 72 hours and was suspended
in distilled water at doses of 100, 200, and 350 mg/kg
body weight (bw).
Preparation of the alloxan-induced diabetic Wistar rats
Diabetes was induced in rats that fasted for 18 hours by
a single intraperitoneal injection of alloxan monohydrate
(120 mg/kg) freshly dissolved in cold citrate buffer
(pH=4.5) subcutaneously. At 72 hours following the
injection, we confirmed hyperglycemia in the rats via
blood samples from the tail vein which were measured
by a glucometer device (On Call Now, San Diego, CA,
USA). The animals were considered diabetic if their
blood glucose levels were 300 mg/dl or higher for two
consecutive measurements.
Experimental design
Rats were randomly divided into 8 groups of 12 rats
per group and placed in cages (two rats per cage). They
were treated orally with PGE for a period of 21 days
as follows: group I normal control (NC): normal rats
treated with vehicle alone. Group II (PGE+Na): normal
rats treated with PGE at a dose of 100 mg/kg bw. Group
III (PGE+Nb): normal rats treated with PGE at a dose
of 200 mg/kg bw. Group IV (PGE+Nc): normal rats
treated with PGE at a dose of 350 mg/kg bw. Group V
diabetic control (DC): diabeticrats treated with vehicle
alone. Group VI (PGE+Da): diabeticrats treated with
PGE at a dose of 100 mg/kg bw. Group VII (PGE+Db):
diabeticrats treated with PGE at a dose of 200 mg/kg bw.
Group VIII (PGE+Dc): diabeticrats treated with PGE
at a dose of 350 mg/kg bw. These doses were selected
based on results obtained in pilot experiments that used
lower doses of PGF (10 and 50 mg/kg/day). These doses
failed to ameliorate hyperglycemia and other clinical
outcomes (data not shown), whereas the selected doses
were found to be efficient. At the end of the experimental
period, the rats fasted overnight and we obtained blood
samples via intra-cardiac puncture (under anesthesia) on
day 21. Blood samples were collected in both ordinary
and lithium heparin tubes. For serum separation, blood
samples were incubated at room temperature to allow for
clotting, and then centrifuged at 1000 g for 15 minutes for
plasma separation from the erythrocytes. Sera were stored
in aliquots at -70˚C until biochemical analysis. Liver and
skeletal muscle tissues were collected, weighed, and
frozen in liquid nitrogen, and stored at -180˚C.
Biochemical analysis
We assessed β-cell function in the experimental groups
by measuring serum insulin levels by the ELISA method
(Demeditec, Germany) according to the manufacturers’
instructions. The plasma TG and free fatty acid (FFA)
analyses were performed on the samples, which were
collected at the end of the experimental period (day 21).
Samples were then quantified using Triglyceride and
Free Fatty Acid Quantification Assay kits, according to
the manufacturers’ instructions. To estimate the effect
of PGE administration on the TG level of the liver and
skeletal muscle tissues, portions of the samples obtained
from the control and treated groups were suspended and
homogenized in 1 ml of 5% NP-40/ddH2O, boiled, and
later centrifuged at 12000 g for 2 minutes. The tissue
TG concentrations were analyzed using the same kit as
described for the plasma TG analysis. ELISA assay was
performed to assess the ROS levels in the plasma, liver,
and skeletal muscle tissues of the experimental groups.
Collected samples were prepared and subjected to
quantitative analysis with a RatReactive Oxygen Species
ELISA kit according to the manufacturers’ protocol.
To determine the glycogen content in the liver and skeletal
muscle, tissue samples were dissolved in 30% KOH,
boiled, and later centrifuged at 12000 g for 5 minutes.
Glycogen was measured in the supernatants with a
commercial glycogen assay kit.
RNA extraction and real-time polymerase chain
reaction analysis
Total RNA was extracted from the homogenized suspension
of the target tissues using a Polytron PT1600E bench-top
homogenizer (Kinematica AG, Switzerland) and RNX-Plus
reagent kit according to the manufacturers’ instructions.
The RNA concentration was measured by a Nanodrop ND-
1000 spectrophotometer (Nanodrop Technologies), and the
quality was assayed by measuring the A260/A280 ratio of
1.8-2.0. A total of 1 μg total RNA was reverse-transcribed
with the PrimeScript RT reagent kit. Quantitative real-time
reverse transcription-PCR was carried out on an ABI Step
One RT-PCR thermal cycler (ABI Stepone, NY, USA) using
a YTA SYBR green qPCR masterMix 2X kit according to
the manufacturers’ instructions. Primer sequences were
designed for all genes using PerlPrimer. Primer-BLAST
(NCBI) was then used to check their specificity. Ribosomal
18S RNA was utilized to calculate the relative abundance
of the mRNA transcripts. We assessed RNA integrity by
measuring ribosomal 28S RNA levels. Each measurement
was performed in triplicate. The primer sequences for realtime
PCR were as follows:F: 5ˊ-CTACTAAGGTCGTGAGACGCTGCC-3ˊR: 5ˊ-TCAGCATACAGGTTTCCTTCCACC-3ˊF: 5ˊ-CTTCTGGGCCATATGTGGAGA-3ˊR: 5ˊ-TCGCACTTGTAACGGAAACG-3ˊF: 5ˊ-GATACCGATGGCTTCTCAGACG-3ˊR: 5ˊ-TCGTTCTCATAATACTCCAGGCG-3ˊF:5ˊ-GGACACGGACAGGATTGACA-3ˊR: 5ˊ-ACCCACGGAATCGAGAAAGA-3ˊF:5ˊ-GGTAAACGGCGGGAGTAACTATG-3ˊR: 5ˊ-TAGGTAGGGACAGTGGGAATCTCG-3ˊ5ˊ- GUCCAGUUUUCCCAGGAAUCCCU-3ˊ
MicroRNA extraction and real-time-polymerase chain
reaction analysis
The miRNAs were extracted from the plasma and
homogenized suspension of liver and skeletal muscle
tissues using the miRNA isolation kit according to
the manufacturers’ instructions. The concentration of
purified RNA was determined in the Nanodrop ND-
1000 spectrophotometer and quality was estimated
by A260/A280 ratio of 1.8-2.0. We added the UniSp6
RNA Spike-in template to each sample. A total of 1 μg
of the miRNA samples was reverse-transcribed with the
Universal cDNA synthesis kit II. Quantitative real-time
reverse transcription-polymerase chain reaction (PCR)
was carried out on an ABI Step One RT-PCR thermal cycler,
using a specific miR-145 LNA™ primer (Exiqon, USA) and
ExiLENT SYBR® Green PCR Master Mix that contained
the miScript Universal reverse primer, according to the
manufacturers’ instructions. Relative miRNA abundance was
determined by normalization to U6 using the 2-ΔΔCT method.
Statistical analysis
All data are mean ± SD. Comparisons between groups
were made by one-way analysis of variance (ANOVA)
followed by an appropriate post-hoc test to analyze the
difference. Statistical significance was achieved at P<0.05.
Results
Pomegranate fruit aqueous extract increases the
insulin level in diabetic rats
In comparison with the control group, we observed
decreased serum insulin levels in the DCrats (Fig .1A).
In contrast to DC, the daily PGE intake elevated insulin
levels in the diabetic groups, as with PGE+Dc, the data
were statistically significant (P<0.001). SPSS software
version 20 (SPSS Inc, USA) was used in this study.
Fig.1
Biochemical analysis in the experimental rats. Effects of pomegranate fruit aqueous extract (PGE) on A. Insulin, B. Fasting blood glucose, C. Free
fatty acid (FFA), and D. Triglyceride (TG) concentrations were evaluated in the non-diabetic control group (NC, n=12), non-diabetic group treated with 100,
200, or 350 mg/kg body weight (bw) of pomegranate fruit aqueous extract [PGE+N (a, b, c); n=12], diabetic control group (DC, n=12), and diabetic group
treated with 100, 200, or 350 mg/kg bw of PGE [PGE+D (a, b, c); n=12]. Each value is the mean ± SD of six separate experiments.
The impact of pomegranate fruit aqueous extract
consummation on hyperglycemia
We measured glucose concentrations were measured in the
target groups after 7, 14, and 21 days (Fig .1B). In DCrats,
fasting blood glucose (FBG) values increased significantly.
The proportion of FBG in the PGE treated animals, however,
reduced compared to the first day and DC controls (P<0.001).
Pomegranate fruit aqueous extract improves
hyperlipidemia in target groups
Prolonged PGE treatment showed a promising reduction
in plasma FFA and TG concentrations compared to the
DC group (Fig .1C, D). The PGE+Dcrats, however, had
significant differences (P<0.001).
Administration of pomegranate fruit aqueous extract
reduces reactive oxygen species level in alloxandiabetic
rats
We determined serum ROS concentrations in the
experimental groups during a 3-week treatment period with
PGE. When compared with the healthy controls, DCrats
showed additive ROS levels during diabetes progression
(Fig .2A). This process reversed in the PGE treated groups
and significantly reduced in the PGE+Dcrats (P<0.001).
Pancreatic ROS levels were assessed to determine the effect of
prolonged treatment on β islets (Fig .2B), and liver and skeletal
muscle tissues (Fig .2C). As expected, ROS accumulation
significantly decreased in PGE administered diabeticrats
compared to DC controls (P<0.001). Interestingly, normal
rats that received the extract also exhibited smaller amounts
of ROS production in their serum, as well as in the pancreas,
liver and skeletal muscle tissues.
Fig.2
The evaluation of the reactive oxygen species (ROS) contents. Analysis were performed on A. Serum, B. β-cells, and C. Intracellular of alloxan-diabetic rats.
NC; Normal control (n=12), DC; Diabetic control (n=12), pomegranate fruit aqueous extract (PGE)+N (a, b, c); Normal rats treated with 100, 200, or 350
mg/kg body weight (bw) of PGE (n=12), PGE+D (a, b, c); Diabetic rats treated with 100, 200, or 350 mg/kg bw of PGE (n=12), Significantly different from
DC group, *; P<0.05, **; P<0.01, and ***; P<0.001. Each value is the mean ± SD of six separate experiments.
Biochemical analysis in the experimental rats. Effects of pomegranate fruit aqueous extract (PGE) on A. Insulin, B. Fasting blood glucose, C. Free
fatty acid (FFA), and D. Triglyceride (TG) concentrations were evaluated in the non-diabetic control group (NC, n=12), non-diabetic group treated with 100,
200, or 350 mg/kg body weight (bw) of pomegranate fruit aqueous extract [PGE+N (a, b, c); n=12], diabetic control group (DC, n=12), and diabetic group
treated with 100, 200, or 350 mg/kg bw of PGE [PGE+D (a, b, c); n=12]. Each value is the mean ± SD of six separate experiments.The evaluation of the reactive oxygen species (ROS) contents. Analysis were performed on A. Serum, B. β-cells, and C. Intracellular of alloxan-diabeticrats.
NC; Normal control (n=12), DC; Diabetic control (n=12), pomegranate fruit aqueous extract (PGE)+N (a, b, c); Normal rats treated with 100, 200, or 350
mg/kg body weight (bw) of PGE (n=12), PGE+D (a, b, c); Diabeticrats treated with 100, 200, or 350 mg/kg bw of PGE (n=12), Significantly different from
DC group, *; P<0.05, **; P<0.01, and ***; P<0.001. Each value is the mean ± SD of six separate experiments.
Pomegranate fruit aqueous extract ameliorates p53
and p65 overexpression
In the alloxandiabeticrats, p53 expression
upregulated in response to a high level of ROS
production, which significantly differed from those
in the NC group (Fig .3A). Oral PGE administration
(350 mg/kg bw) resulted in a marked reduction of the
p53 expression level in the diabeticrats (P<0.01).
The level of p65 expression, as a subunit of the
transcription factor NF-κB complex, increased with
diabetes progression (Fig .3B). The PGE+Dc treated
group had a lower level of p65 (P<0.001), which
closely approximated the healthy controls.
Fig.3
Quantitative real-time polymerase chain reaction analysis of the
inflammatory transcription factors. The levels of the A. p53 and B. p65 were
measured in the liver and skeletal muscle tissues of non-diabetic control group
(NC, n=12), non-diabetic group treated with 100, 200, or 350 mg/kg body
weight (bw) of pomegranate fruit aqueous extract [PGE+N (a, b, c); n=12],
diabetic control group (DC, n=12), and diabetic group treated with 100, 200,
or 350 mg/kg bw of PGE [PGE+D (a, b, c), n=12]. Results are expressed as fold
of control. 18s RNA was used as an internal control (n=3). The mean of six
independent experiments is shown. Significantly different from DC group, *;
P<0.05, **; P<0.01, and ***; P<0.001.
Quantitative real-time polymerase chain reaction analysis of the
inflammatory transcription factors. The levels of the A. p53 and B. p65 were
measured in the liver and skeletal muscle tissues of non-diabetic control group
(NC, n=12), non-diabetic group treated with 100, 200, or 350 mg/kg body
weight (bw) of pomegranate fruit aqueous extract [PGE+N (a, b, c); n=12],
diabetic control group (DC, n=12), and diabetic group treated with 100, 200,
or 350 mg/kg bw of PGE [PGE+D (a, b, c), n=12]. Results are expressed as fold
of control. 18s RNA was used as an internal control (n=3). The mean of six
independent experiments is shown. Significantly different from DC group, *;
P<0.05, **; P<0.01, and ***; P<0.001.
Pomegranate fruit aqueous extract downregulates
miR-145 expression in diabetic rats
In comparison to the control group, miR-145
expression upregulated in the plasma (3.7-fold,
Fig .4A), and liver (2.3-fold) and skeletal muscle (2.1-
fold) tissues (Fig .4B) of DCrats (P<0.001). Of note,
the values obtained for the PGE+Dcrats were similar
to the NC group.
Fig.4
Quantitative real-time polymerase chain reaction analysis of the
miR-145 expression levels. The examinations were performed on A.
Plasma, B. Liver and skeletal muscle tissues of non-diabetic control group
(NC, n=12), non-diabetic group treated with 100, 200, or 350 mg/kg
body weight (bw) of pomegranate fruit aqueous extract [PGE+N (a, b, c);
n=12], diabetic control group (DC, n=12), and diabetic group treated with
100, 200, or 350 mg/kg bw of PGE [PGE+D (a, b, c); n=12]. Results are
expressed as fold of control. U6 was used as an endogenous control (n=3).
The mean of six independent experiments is shown. Significantly different
from DC group, *; P<0.05, **; P<0.01, and ***; P<0.001.
Quantitative real-time polymerase chain reaction analysis of the
miR-145 expression levels. The examinations were performed on A.
Plasma, B. Liver and skeletal muscle tissues of non-diabetic control group
(NC, n=12), non-diabetic group treated with 100, 200, or 350 mg/kg
body weight (bw) of pomegranate fruit aqueous extract [PGE+N (a, b, c);
n=12], diabetic control group (DC, n=12), and diabetic group treated with
100, 200, or 350 mg/kg bw of PGE [PGE+D (a, b, c); n=12]. Results are
expressed as fold of control. U6 was used as an endogenous control (n=3).
The mean of six independent experiments is shown. Significantly different
from DC group, *; P<0.05, **; P<0.01, and ***; P<0.001.
Effect of pomegranate fruit aqueous extract treatment
on irs-1 level in target rats
The transcription levels of irs-1 were examined in the
NC, DC, and PGE-treated groups (Fig .5). irs-1 expression
significantly reduced in the DC group. In contrast, irs-1
expression increased in the PGE+Db and PGE+Dcrats.
Fig.5
Quantitative real-time polymerase chain reaction analysis of the
insulin receptor substrate 1 (irs-1) expression levels. The tests were
carried out on the liver and skeletal muscle tissues of the non-diabetic
control group (NC, n=12), non-diabetic group treated with 100, 200,
or 350 mg/kg body weight of pomegranate fruit aqueous extract
[PGE+N (a, b, c); n=12], diabetic control group (DC, n=12), and diabetic
group treated with 100, 200, or 350 mg/kg bw of PGE [PGE+D (a, b, c);
n=12]. Results are expressed as fold of control. 18s RNA was used as
an internal control (n=3). The mean of six independent experiments
is shown. Significantly different from DC group, *; P<0.05, **; P<0.01,
and ***; P<0.001.
Quantitative real-time polymerase chain reaction analysis of the
insulin receptor substrate 1 (irs-1) expression levels. The tests were
carried out on the liver and skeletal muscle tissues of the non-diabetic
control group (NC, n=12), non-diabetic group treated with 100, 200,
or 350 mg/kg body weight of pomegranate fruit aqueous extract
[PGE+N (a, b, c); n=12], diabetic control group (DC, n=12), and diabetic
group treated with 100, 200, or 350 mg/kg bw of PGE [PGE+D (a, b, c);
n=12]. Results are expressed as fold of control. 18s RNA was used as
an internal control (n=3). The mean of six independent experiments
is shown. Significantly different from DC group, *; P<0.05, **; P<0.01,
and ***; P<0.001.
Impact of the pomegranate fruit aqueous extract on
triglyceride and glycogen contents in liver and skeletal
muscle tissues
The DC group had the lowest levels of TG and glycogen
storages (P<0.001, Fig .6). In the PGE group, uptake
increased the TG levels and glycogen storages in diabeticrats close to the levels of the NC group.
Fig.6
Effects of pomegranate fruit aqueous extract (PGE) on the
glycogen and triglyceride (TG) contents. The examinations were
performed on the A, B. Liver and skeletal muscle, C. and D. Tissues
of the normal control group (NC, n=12), non-diabetic group treated
with 100, 200, or 350 mg/kg body weight (bw) of PGE [PGE+N (a, b, c);
n=12], diabetic control group (DC, n=12), and diabetic group treated
with 100, 200, or 350 mg/kg bw of PGE [PGE+D (a, b, c); n=12]. Each
value is the mean ± SD of six separate experiments. Significantly
different from DC group, *; P<0.05, **; P<0.01, and ***; P<0.001.
Effects of pomegranate fruit aqueous extract (PGE) on the
glycogen and triglyceride (TG) contents. The examinations were
performed on the A, B. Liver and skeletal muscle, C. and D. Tissues
of the normal control group (NC, n=12), non-diabetic group treated
with 100, 200, or 350 mg/kg body weight (bw) of PGE [PGE+N (a, b, c);
n=12], diabetic control group (DC, n=12), and diabetic group treated
with 100, 200, or 350 mg/kg bw of PGE [PGE+D (a, b, c); n=12]. Each
value is the mean ± SD of six separate experiments. Significantly
different from DC group, *; P<0.05, **; P<0.01, and ***; P<0.001.
Discussion
In T1DM, immune system cells (T cells and
macrophages) act against β-cells by secreting proinflammatory
cytokines TNF-α, nitric oxide and
ROS, which eventually induce the destruction of
β-pancreatic islets (insulitis) (6). Thus, depletions
in β-cells lead to decreased insulin secretion and
concentration in the body, hyperglycemia, and
hyperlipidemia. Elevations in blood glucose have been
proven to be strong stimulators of ROS generation
in diabetic models (18). For in vivo studies, ROSmediated
β-cell destruction in rats is established by an
injection of alloxan monohydrate. This compound is
an oxygenated pyrimidine derivative exclusively taken
up by Glut-2 transporters. Alloxan and its reductive
product, dialuric acid, create a redox cycle which
generates abundant superoxide radicals. Eventually,
due to the low levels of antioxidant enzymes, such
as catalase, ROS molecules accumulate in β-cells,
resulting in inflammation and apoptosis (19) .p53 is one of the apoptotic mediator proteins that activates
in response to ROS elevation and plays a transcription
factor role in recruiting the expression of genes involved
in cell death or survival (19). Previous investigations have
reported an elevated level of p53 expression according to
oxidative stress in alloxan-induced diabeticrats (20). A
p53 response element is located in the promoter region of
miR-145, which upregulates its expression (8) and may
be involved in miR-145 activation during oxidative stress
situations (21). According to these evidences, we have
hypothesized that ROS accumulation in alloxan-diabeticrats accelerates hyperglycemia and hyperlipidemia
through the enhancement of miR-145 expression levels.Our experiments demonstrated an accelerated level
of p53 gene expression in the liver and skeletal muscle
tissues of diabeticrats, in response to massive ROS
production followed by high miR-145 expression in target
tissues, as well as plasma. IRS-1 is a vital mediator in the
insulin metabolic signaling pathway downregulated by
miR-145. During the postprandial phase, insulin hormone
actives the IRS-1/phosphatidylinositol 3-kinase/protein
kinase B (IRS-1/PI3K/Akt) cascade and upregulates
glucose uptake and storage (22), lipid synthesis (23) and
attenuates lipolysis (24) in cells.Previous studies have explored the effects of the
polyphenols on regulation of miRNAs in cancer (25,
26); however, to our knowledge, there is scant evidence
regarding their effects on metabolic complications (27). In
this study, the DC group has depicted a decreased level of
irs-1 transcription in response to miR-145 overexpression.
In contrast, diabeticrats treated with PGE for 21 days
reversed miR-145 elevation with increased irs-1 mRNA
expression. The same results were obtained from healthy
treated groups, as oral administration of PGE lowered
the basal level of miR-145 expression in all groups
and, conversely, elevated irs-1 levels in the healthy
animals. These data supported clinical findings that
showed PGE consumption improved TG and glycogen
storage in normal groups, as well as diabeticrats.There is a synergy between miR-145 overexpression,
high levels of lipolysis, TNF-α secretion, and NF-kB
activation. In the alloxan-diabeticrats, in response to
ROS accumulation, the NF-kB complex upregulated miR-
145 by binding its p65 subunit to the miR-145 promoter
(9). miR-145 inhibitory effects on the insulin signaling
pathway have been shown to lead to hydrolysis of TG and
FFA release (3). Saturated FFA binds to the macrophage
toll-like receptor 4 (TLR4) and stimulates TNF-α
secretion. TNF-α provokes mitogen-activated protein
kinases (MAPKs) and NF-kB activation by attaching to
TNF-α receptor-1 (TNFR-1). This removes the inhibitory
effect of perilipin-1 (PLIN1) on the hormone-sensitive
lipase (HSL) by downregulation of the PLIN1 expression
and acceleration of its phosphorylation, thus intensify
TG hydrolysis (3). In line with these reports, our results
have revealed that PGE treatment contributed to the
improvement in hyperlipidemia as a result of a reduction
in ROS-mediated p65 induction of miR-145 expression in
alloxan-diabeticrats.
Conclusion
Overall, the present study showed that oral administration
of PGE ameliorated induced hyperglycemia and
hyperlipidemia in alloxan-diabeticrats. With regards to the
formation of an ROS wave in the rats’ pancreatic β-cells
attributed to the alloxan injection, the reductive effect
of pomegranate on ROS accumulation improved β-cell
function and insulin secretion. The PGE components had
a suppressive impact on high p53 and p65 expression
levels in the liver and skeletal muscle tissues of diabeticrats and, accordingly, implicated miR-145 upregulation
by p53/p65 stimulation. Consequently, the decreased irs-1
mRNA level, as a direct target of miR-145, improved in
the intended tissues followed by enhanced glucose
uptake and storage. However, due to the presence of
various active components such as flavonoids in PGE
(as described earlier), further studies should be carried
out to obtain a deeper understanding of the underlying
mechanisms.
Authors: Jessica L Yecies; Hui H Zhang; Suchithra Menon; Sihao Liu; Derek Yecies; Alex I Lipovsky; Cem Gorgun; David J Kwiatkowski; Gökhan S Hotamisligil; Chih-Hao Lee; Brendan D Manning Journal: Cell Metab Date: 2011-07-06 Impact factor: 27.287
Authors: Seong O Suh; Yi Chen; Mohd Saif Zaman; Hiroshi Hirata; Soichiro Yamamura; Varahram Shahryari; Jan Liu; Z Laura Tabatabai; Sanjay Kakar; Guoren Deng; Yuichiro Tanaka; Rajvir Dahiya Journal: Carcinogenesis Date: 2011-02-23 Impact factor: 4.944
Authors: Cong Liu; Zhuo Wang; Yulong Song; Dan Wu; Xuan Zheng; Ping Li; Jin Jin; Nannan Xu; Ling Li Journal: Biomed Res Int Date: 2015-02-01 Impact factor: 3.411